Compile Data Set for Download or QSAR
maximum 50k data
Found 1427 with Last Name = 'lingard' and Initial = 'i'
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423171(US10501440, Example 3)
Affinity DataKi:  0.300nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423183(N-[(5R)-1-Amino-5H,6H,7H-cyclopenta[c]pyridin-5-yl...)
Affinity DataKi:  0.300nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423170(US10501440, Example 2)
Affinity DataKi:  0.300nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423169(N-[(5R)-1-Amino-5H,6H,7H-cyclopenta[c]pyridin-5-yl...)
Affinity DataKi:  0.300nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423180(N-[(5R)-1-Amino-3-methyl-5H,6H,7H-cyclopenta[c]pyr...)
Affinity DataKi:  0.400nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423174(US10501440, Example 5)
Affinity DataKi:  0.400nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423173(US10501440, Example 4)
Affinity DataKi:  0.400nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423179(N-[(5R)-1-Amino-5H,6H,7H-cyclopenta[c]pyridin-5-yl...)
Affinity DataKi:  0.400nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423185(N-[(5R)-1-Amino-3-methyl-5H,6H,7H-cyclopenta[c]pyr...)
Affinity DataKi:  0.400nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423187(N-[(5R)-1-Amino-3-methyl-5H,6H,7H-cyclopenta[c]pyr...)
Affinity DataKi:  0.5nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423188(N-[(5R)-1-Amino-3-methyl-5H,6H,7H-cyclopenta[c]pyr...)
Affinity DataKi:  0.5nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423182(US10501440, Example 12)
Affinity DataKi:  0.600nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423184(US10501440, Example 14)
Affinity DataKi:  1.10nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311944(US10166214, Example 80 | US10675268, Example 80 | ...)
Affinity DataKi:  1.20nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311944(US10166214, Example 80 | US10675268, Example 80 | ...)
Affinity DataKi:  1.20nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311944(US10166214, Example 80 | US10675268, Example 80 | ...)
Affinity DataKi:  1.20nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423181(US10501440, Example 11)
Affinity DataKi:  1.5nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423176(US10501440, Example 7)
Affinity DataKi:  1.90nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423186(N-[(5R)-1-Amino-5H,6H,7H-cyclopenta[c]pyridin-5-yl...)
Affinity DataKi:  2.20nMAssay Description:Human KLKB1 (1.78 nM or 0.025 U/mL; Enzyme Research Laboratories) was incubated at 24° C. with 0.25 mM fluorogenic substrate H-Pro-Phe-Arg-AMC (11295...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311888(US10166214, Example 24 | US10675268, Example 24 | ...)
Affinity DataKi:  2.90nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311888(US10166214, Example 24 | US10675268, Example 24 | ...)
Affinity DataKi:  2.90nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311888(US10166214, Example 24 | US10675268, Example 24 | ...)
Affinity DataKi:  2.90nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311990(US10166214, Example 126 | US10675268, Example 126 ...)
Affinity DataKi:  3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311990(US10166214, Example 126 | US10675268, Example 126 ...)
Affinity DataKi:  3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311990(US10166214, Example 126 | US10675268, Example 126 ...)
Affinity DataKi:  3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  3.40nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  3.40nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  3.40nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311957(US10166214, Example 93 | US10675268, Example 93 | ...)
Affinity DataKi:  3.60nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311957(US10166214, Example 93 | US10675268, Example 93 | ...)
Affinity DataKi:  3.60nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311957(US10166214, Example 93 | US10675268, Example 93 | ...)
Affinity DataKi:  3.60nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081058(CHEMBL3421842 | US10166214, Example 22 | US1067526...)
Affinity DataKi:  3.70nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081058(CHEMBL3421842 | US10166214, Example 22 | US1067526...)
Affinity DataKi:  3.70nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081058(CHEMBL3421842 | US10166214, Example 22 | US1067526...)
Affinity DataKi:  3.70nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081055(CHEMBL3421843 | US10166214, Example 49 | US1067526...)
Affinity DataKi:  4.5nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081055(CHEMBL3421843 | US10166214, Example 49 | US1067526...)
Affinity DataKi:  4.5nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081055(CHEMBL3421843 | US10166214, Example 49 | US1067526...)
Affinity DataKi:  4.5nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311992(US10166214, Example 128 | US10675268, Example 128 ...)
Affinity DataKi:  7.60nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311992(US10166214, Example 128 | US10675268, Example 128 ...)
Affinity DataKi:  7.60nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311992(US10166214, Example 128 | US10675268, Example 128 ...)
Affinity DataKi:  7.60nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311885(US10166214, Example 21 | US10675268, Example 21 | ...)
Affinity DataKi:  10.8nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311885(US10166214, Example 21 | US10675268, Example 21 | ...)
Affinity DataKi:  10.8nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311885(US10166214, Example 21 | US10675268, Example 21 | ...)
Affinity DataKi:  10.8nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311958(US10166214, Example 94 | US10675268, Example 94 | ...)
Affinity DataKi:  15.9nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311958(US10166214, Example 94 | US10675268, Example 94 | ...)
Affinity DataKi:  15.9nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311958(US10166214, Example 94 | US10675268, Example 94 | ...)
Affinity DataKi:  15.9nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM322581(US10183940, Example 33)
Affinity DataKi:  21.7nMAssay Description:Method description for binding assays with human Somatostatin receptors by use of CHO cell membranes expressing recombinant human SSTR1 or human SSTR...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM322587(US10183940, Example 39)
Affinity DataKi:  29.1nMAssay Description:Method description for binding assays with human Somatostatin receptors by use of CHO cell membranes expressing recombinant human SSTR1 or human SSTR...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM312012(US10166214, Example 148 | US10675268, Example 148 ...)
Affinity DataKi:  32.3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM312012(US10166214, Example 148 | US10675268, Example 148 ...)
Affinity DataKi:  32.3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1427 total ) | Next | Last >>
Jump to: